blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3204500

EP3204500 - APTAMERS FOR PURIFYING AND QUANTIFYING GELSOLIN AND ITS VARIANTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.03.2020
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  05.04.2019
FormerGrant of patent is intended
Status updated on  16.01.2019
FormerExamination is in progress
Status updated on  20.04.2018
FormerRequest for examination was made
Status updated on  14.07.2017
FormerThe international publication has been made
Status updated on  07.03.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Council of Scientific and Industrial Research
Anusandhan Bhawan
Rafi Marg
New Delhi / IN
[2019/23]
Former [2017/33]For all designated states
Council of Scientific and Industrial Research
Anusandhan Bhawan
Rafi Marg
New Delhi, Maharashtra 110001 / IN
Inventor(s)01 / ., Ashish
Institute of Microbial Technology
IMTECH
Sector 39-A
Chandigarh / IN
02 / GARG, Renu
Institute of Microbial Technology
IMTECH
Sector 39-A
Chandigarh / IN
03 / PEDDADA, Nagesh
Institute of Microbial Technology
IMTECH
Sector 39-A
Chandigarh / IN
 [2017/33]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2019/19]Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Former [2017/33]Oxley, Rachel Louise, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15801954.705.10.2015
[2017/33]
WO2015IN50128
Priority number, dateIN2014DEL285207.10.2014         Original published format: IN 2852DE2014
[2017/33]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016056028
Date:14.04.2016
Language:EN
[2016/15]
Type: A2 Application without search report 
No.:EP3204500
Date:16.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 14.04.2016 takes the place of the publication of the European patent application.
[2017/33]
Type: B1 Patent specification 
No.:EP3204500
Date:08.05.2019
Language:EN
[2019/19]
Search report(s)International search report - published on:EP02.06.2016
ClassificationIPC:C12N15/115, G01N33/50
[2017/33]
CPC:
C12N15/115 (EP,RU,US); G01N33/6872 (EP,RU,US); C07K1/22 (US);
C07K14/4702 (EP,RU,US); G01N33/5308 (US); G01N33/68 (US);
C12N2310/16 (EP,RU,US); C12N2320/10 (US); G01N2333/4703 (US);
G01N2333/4727 (EP,RU,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/33]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:APTAMERE ZUR REINIGUNG UND QUANTIFIZIERUNG VON GELSOLIN UND DESSEN VARIANTEN[2017/33]
English:APTAMERS FOR PURIFYING AND QUANTIFYING GELSOLIN AND ITS VARIANTS[2017/33]
French:APTAMÈRES POUR LA PURIFICATION ET LA DÉTERMINATION QUANTITATIVE DU GELSOLINE ET DE SES VARIANTS[2017/33]
Entry into regional phase17.03.2017National basic fee paid 
17.03.2017Designation fee(s) paid 
17.03.2017Examination fee paid 
Examination procedure22.06.2016Request for preliminary examination filed
International Preliminary Examining Authority: EP
07.03.2017Date on which the examining division has become responsible
17.03.2017Examination requested  [2017/33]
23.04.2018Despatch of a communication from the examining division (Time limit: M04)
30.08.2018Reply to a communication from the examining division
17.01.2019Communication of intention to grant the patent
26.03.2019Fee for grant paid
26.03.2019Fee for publishing/printing paid
26.03.2019Receipt of the translation of the claim(s)
Opposition(s)11.02.2020No opposition filed within time limit [2020/16]
Fees paidRenewal fee
29.09.2017Renewal fee patent year 03
20.09.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.10.2015
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MK08.05.2019
MT08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
IE05.10.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
FR31.10.2019
LI31.10.2019
[2022/31]
Former [2021/34]HU05.10.2015
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MT08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
IE05.10.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
FR31.10.2019
LI31.10.2019
Former [2021/32]HU05.10.2015
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
IE05.10.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
FR31.10.2019
LI31.10.2019
Former [2021/31]AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
IE05.10.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
FR31.10.2019
LI31.10.2019
Former [2021/26]AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
IE05.10.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
FR31.10.2019
LI31.10.2019
Former [2020/49]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
IE05.10.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
FR31.10.2019
LI31.10.2019
Former [2020/46]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
IE05.10.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
LI31.10.2019
Former [2020/38]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
LU05.10.2019
BE31.10.2019
CH31.10.2019
LI31.10.2019
Former [2020/35]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
LU05.10.2019
CH31.10.2019
LI31.10.2019
Former [2020/34]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
CH31.10.2019
LI31.10.2019
Former [2020/29]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/25]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/17]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/14]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/12]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/11]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/10]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/09]AL08.05.2019
CZ08.05.2019
DK08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/51]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/50]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/49]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
NL08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/48]ES08.05.2019
FI08.05.2019
LT08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/47]ES08.05.2019
FI08.05.2019
LT08.05.2019
NO08.08.2019
Cited inInternational search[Y]  - HAVERLAND NICOLE ET AL, "Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, (20101220), vol. 8, no. 1, doi:10.1186/1479-5876-8-137, ISSN 1479-5876, page 137, XP021088855 [Y] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1186/1479-5876-8-137
 [Y]  - STOLTENBURG ET AL, "SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands", BIOMOLECULAR ENGINEERING, ELSEVIER, NEW YORK, NY, US, (20070916), vol. 24, no. 4, doi:10.1016/J.BIOENG.2007.06.001, ISSN 1389-0344, pages 381 - 403, XP022251573 [Y] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bioeng.2007.06.001
by applicant   - ARNDT-JOVIN DJ; JOVIN TM; BAHR W; FRISCHAUF AM; MARQUARDT M, "Covalent attachment of DNA to agarose. Improved synthesis and use in affinity chromatography", EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS, (1975), vol. 54, pages 411 - 418
    - ASHISH, PAINE MS; PERRYMAN PB; YANG L; YIN HL; KRUEGER JK, "Global structure changes associated with Ca2+ activation of full-length human plasma gelsolin", J BIOL CHEM, (2007), vol. 282, pages 25884 - 25892
    - BUCKI R; BYFIELD FJ; KULAKOWSKA A; MCCORMICK ME; DROZDOWSKI W; NAMIOT Z; HARTUNG T; JANMEY PA, "Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to . proinflammatory bacterial wall components", JOURNAL OF IMMUNOLOGY, (2008), vol. 181, pages 4936 - 4944
    - BUCKI R; GEORGES PC; ESPINASSOUS Q; FUNAKI M; PASTORE JJ; CHABY R; JANMEY PA, "Inactivation of endotoxin by human plasma gelsolin", BIOCHEMISTRY, (2005), vol. 44, doi:doi:10.1021/bi0503504, pages 9590 - 9597, XP002582953

DOI:   http://dx.doi.org/10.1021/bi0503504
    - BUCKI R; KULAKOWSKA A; BYFIELD FJ; ZENDZIAN-PIOTROWSKA M; BARANOWSKI M; MARZEC M; WINER JP; CICCARELLI NJ; GORSKI J; DROZDOWSKI W, "Plasma gelsolin modulates cellular response to sphingosine I-phosphate", AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY, (2010), vol. 299, pages C 1516 - 1523
    - GARG R; PEDDADA N; SAGAR A; NIHALANI D; ASHISH, "Visual insight into how low pH alone can induce actin-severing ability in gelsolin under calcium-free conditions", BIOL CHEM, (2011), vol. 286, pages 20387 - 20397
    - ITO H; KAMBE H; KIMURA Y; NAKAMURA H; HAYASHI E; KISHIMOTO T; KISHIMOTO S; YAMAMOTO H, "Depression of plasma gelsolin level during acute liver injury", GASTROENTEROLOGY, (1992), vol. 102, pages 1686 - 1692, XP008083048
    - KADONAGA JT; TJIAN R, "Affinity purification of sequence-specific DNA binding proteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1986), vol. 83, pages 5889 - 5893
    - KWIATKOWSKI DJ; MEHL R; IZUMO S; NADAL-GINARD B; YIN HL, "Muscle is the major source of plasma gelsolin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1988), vol. 263, pages 8239 - 8243
    - KWIATKOWSKI DJ; STOSSEL TP; ORKIN SH; MOLE JE; COLTEN HR; YIN HL, "Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain", NATURE, (1986), vol. 323, doi:doi:10.1038/323455a0, pages 455 - 458, XP002911329

DOI:   http://dx.doi.org/10.1038/323455a0
    - LEE PS; WAXMAN AB; COTICH KL; CHUNG SW; PERRELLA MA; STOSSEL TP, "Plasma gelsolin is a marker and therapeutic agent in animal sepsis", CRIT CARE MED, (2007), vol. 35, doi:doi:10.1097/01.CCM.0000253815.26311.24, pages 849 - 855, XP008122402

DOI:   http://dx.doi.org/10.1097/01.CCM.0000253815.26311.24
    - LEE WM; GALBRAITH RM, "The extracellular actin-scavenger system and actin toxicity", N ENGL J MED, (1992), vol. 326, pages 1335 - 1341, XP000863572
    - LIND SE; JANMEY PA, "Human plasma gelsolin binds to fibronectin", J BIOL CHEM, (1984), vol. 259, pages 13262 - 13266
    - LIND SE; SMITH DB; JANMEY PA; STOSSEL TP, "Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury", AM REV RESPIR DIS, (1988), vol. 138, pages 429 - 434, XP001041297
    - LOFBERG M; PAUNIO T; TAHTELA R; KIURU S; SOMER H, "Serum gelsolin and rhabdomyolysis", J NEUROL SCI, (1998), vol. 157, pages 187 - 190
    - OSBORN TM; DAHLGREN C; HARTWIG JH; STOSSEL TP, "Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin", AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY, (2007), vol. 292, pages C 1323 - 1330
    - OSBORN TM; VERDRENGH M; STOSSEL TP; TARKOWSKI A; BOKAREWA M, "Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis", ARTHRITIS RESEARCH & THERAPY, (2008), vol. 10, doi:doi:10.1186/ar2520, page R117, XP021046820

DOI:   http://dx.doi.org/10.1186/ar2520
    - PAN W; CLAWSON GA, "The shorter the better: reducing fixed primer regions of oligonucleotide libraries for aptamer selection", MOLECULES, (2009), vol. 14, doi:doi:10.3390/molecules14041353, pages 1353 - 1369, XP055310612

DOI:   http://dx.doi.org/10.3390/molecules14041353
    - PEDDADA N; SAGAR A; ASHISH, GARG R, "Plasma gelsolin: a general prognostic marker of health", MED HYPOTHESES, (2012), vol. 78, pages 203 - 210 0
    - PEDDADA N; SAGAR A; RATHORE YS; CHOUDHARY V; PATTNAIK UB; KHATRI N; GARG R, ASHISH, "Global shapes of F-actin depolymerization-competent minimal gelsolins: insight into the role of g2-g3 linker in pH/Ca2+ insensitivity of the first half", J BIOL CHEM, (2013), vol. 288, pages 28266 - 28282
    - SMITH DB; JANMEY PA; SHERWOOD JA; HOWARD RJ; LIND SE, "Decreased plasma gelsolin levels in patients with Plasmodium falciparum malaria: a consequence of hemolysis?", BLOOD, (1988), vol. 72, pages 214 - 218, XP008130952
    - SUHLER E; LIN W; YIN HL; LEE WM, "Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis", CRIT CARE MED, (1997), vol. 25, pages 594 - 598, XP008122382
    - SUN HQ; YAMAMOTO M; MEJILLANO M; YIN HL, "Gelsolin, a multifunctional actin regulatory protein", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1999), vol. 274, pages 33179 - 33182
    - VOUYIOUKLIS DA; BROPHY PJ, "A novel gelsolin isoform expressed by oligodendrocytes in the central nervous system", JOURNAL OF NEUROCHEMISTRY, (1997), vol. 69, pages 995 - 1005
    - WEN D; CORINA K; CHOW EP; MILLER S; JANMEY PA; PEPINSKY RB, "The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure", BIOCHEMISTRY, (1996), vol. 35, pages 9700 - 9709
    - YIN HL; KWIATKOWSKI DJ; MOLE JE; COLE FS, "Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin", JBIOL CHEM, (1984), vol. 259, pages 5271 - 5276
    - YIN HL; STULL JT, "Proteins that regulate dynamic actin remodeling in response to , membrane signaling minireview series", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1999), vol. 274, pages 32529 - 32530
    - YU FX; ZHOU DM; YIN HL, "Chimeric and truncated gCap39 elucidate the requirements for actin filament severing and end capping by the gelsolin family of proteins", J BIOL CHEM, (1991), vol. 266, pages 19269 - 19275
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.